Moderna reported a surprise third-quarter profit on Thursday, driven by cost cutting and higher-than-expected sales of its ...

Moderna shares jumped after the biotechnology company reported higher-than-expected sales of its Covid-19 vaccine and backed ...

(Reuters) -Moderna said on Friday Canada's health regulator has approved its vaccine for respiratory syncytial virus in ...

Days after Pfizer and BioNTech reported surprisingly strong sales of their updated COVID-19 vaccines, Moderna has done the ...

Moderna delivered better-than-expected profit and sales in the third quarter after an early start to sales of this season’s ...

Moderna's stock faces a decline as analysts lower the price target to $90, citing weaker vaccine demand and concerns over ...

Moderna Inc.’s stock jumped 5% early Thursday, after the company’s third-quarter earnings showed an unexpected profit and ...

Sales of Moderna’s COVID-19 shot exceeded expectations, but the company’s launch of its new RSV vaccine has started slowly.

Heading into Moderna’s third-quarter earnings, investors and analysts will be watching to see how the Cambridge drugmaker ...

Moderna said its newest Covid vaccine saw benefits after winning approval in the U.S. three weeks earlier than the last iteration of the shot did in 2023.

Q3 results confirms that the U.S. vaccine market for respiratory syncytial virus (RSV), led by Pfizer (PFE) and GSK (GSK), is ...

Moderna reported earnings that exceeded expectations due to effective cost management but still has challenges related to its ...